Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn
NCT ID: NCT02068807
Last Updated: 2014-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2011-01-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Breastfeeding is important for the contribution of the antioxidant defenses of the newborn and the nutritional status of the mother plays a key role because it influences the nutritional status of the newborn. Lutein is a carotenoid that is not produced by the body , but taken with food or supplements. The molecule carries out different activities : antioxidant, anti-inflammatory, anticancer , neuroprotective. Its main activity of inhibition of peroxidation of membrane lipids is peculiarly important for the photoreceptors and neurons whose membranes are rich with polyunsaturated fatty acids. Current evidence on its role as an antioxidant indicate that supplementation with lutein may play a significant role in the prevention of free radical disease in the newborn
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Synthesis of Glutathione From Low Birth Weight Newborn Babies
NCT00607061
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
NCT05934318
Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.
NCT04819893
The Effect of Light on the Fetal Biophysical Profile
NCT02453230
Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy
NCT00571766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are many evidences that suggest a protective effect of lutein against photo-oxidation damage in adult (Leeuwen 2006, AREDS 1, AREDS 2).
Lutein and zeaxanthin are present in the umbilical cord and several studies have shown that there is a direct correlation between mother and newborn plasma levels of lutein. Lutein is also present in breast milk in concentrations three times higher than other carotenoids with the same plasma concentrations. There is also a correlation between plasma levels of lutein in the mother and levels in the breastfed infant. Studies on infants have shown that carotenoids levels in the first four/six months of life are very low. This is probably due to the fact that the infants diet is entirely made of milk without solid foods (such as green leafy vegetables) sources of this nutrient. Children breastfed have higher lutein plasma levels than children fed with formula milk. The different types of formula milks are currently not enriched with these carotenoids and their content of both lutein and zeaxanthin is very low, except for some formulations which are prepared using egg homogenate but they are not sold in Italy. Breast milk is therefore the only source of lutein for infants before the weaning, and the breastfeeding is very important as a primary source of these nutrients for the proper development and protection of the vision. Considering the correlation between lutein content in plasma and in breast milk and the lowering of lutein levels in milk already six days after birth, it is really important to take foods rich in lutein during lactation. A diet enriched with lutein is especially important for mothers of premature or low birth weight newborns. Indeed the premature and underweight children need many nutrients essential for a rapid growth because they did not receive highly nutritious elements and energy transferred from the mother during the last weeks of gestation. Moreover, their gastrointestinal and renal functions are not fully developed and this could reduce the absorption and retention of some micronutrients including important antioxidants that protect the infant from exposure to high levels of free radicals produced in excess at birth and often as a result of the resuscitation technics used. Breastfeeding is important for the intake of antioxidant defenses in the newborn and the nutritional status of the mother plays certainly a key role because it affects the nutritional status of the infant, and especially the status of some soluble nutrients such as lutein and zeaxanthin. The preparations of lutein and zeaxanthin have never had gastrointestinal or systemic toxic effects in humans after supplementation. In recent studies, no adverse effects after administration of 20 mg/day of lutein or zeaxanthin administered for 6 months or interactions with other fat-soluble nutrients were reported.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lutein drops
oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
Lutein drops
After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
Glucose drops
oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
Glucose drops
After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lutein drops
After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
Glucose drops
After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1 Minute
5 Minutes
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Careggi Hospital
OTHER
University of Siena
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuseppe Buonocore
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Buonocore, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Siena
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOUS
Siena, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perrone S, Tei M, Longini M, Santacroce A, Turrisi G, Proietti F, Felici C, Picardi A, Bazzini F, Vasarri P, Buonocore G. Lipid and protein oxidation in newborn infants after lutein administration. Oxid Med Cell Longev. 2014;2014:781454. doi: 10.1155/2014/781454. Epub 2014 Apr 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEO-LUT-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.